Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002)
Neoadjuvant triple therapy offers OS and EFS benefits for patients with resectable intermediate or advanced HCC, but is associated with an increased risk of adverse events and postoperative complications.
Authors
- Si-cong Lu
- Hongbing Yao (ORCID: https://orcid.org/0000-0002-9177-1251)
- Yao-zhi Chen
- Xiu-Mei Liang
- Qingqing Pang
- Yong-Rong Liang
- Ze Su (ORCID: https://orcid.org/0009-0000-1360-0783)
- Fan-Jian Zeng
- Jian‐Hong Zhong (ORCID: https://orcid.org/0000-0002-1494-6396)
- Fu-Xin Li
- Da-Long Yang (ORCID: https://orcid.org/0000-0002-2931-1166)
- Mian-Jing Li
- Fuquan Yang (ORCID: https://orcid.org/0000-0002-2841-5342)
- Shaoping Liu
- Xiaokai Shen
- Teng-Meng Zhong
- Tian-Man Li (ORCID: https://orcid.org/0000-0003-4397-6663)
- Yongyu Yang (ORCID: https://orcid.org/0000-0001-6239-9262)
- Pei‐Sheng Wu
- X H Mao
- Yih‐Loong Lai
- X. Wu (ORCID: https://orcid.org/0009-0002-0536-106X)
- Jun‐Jie Ou (ORCID: https://orcid.org/0009-0003-2700-1118)
- Jun-Liang Nong
- Ying Xue Wu
- Zhu-Jian Deng
- Jie. Liu
- Zhi-Dong Liu
- Xue-Yao Wang
- Min Luo
- Shu-Qun Li
- Guo-Gao Qiu
- Lin Ye
- Xiao-Feng Dong
- Yao-Ming Wang
- Ting Quan
- Lei Liu
- Wen-Hai He
- Kang Chen
- Guo-Dong Wang
- Ying-Yu Zhang
- Shu-Chang Chen
- Zhi-Jun Jiang
- Wen-Feng Li
- Jia-Liang Wei
- Zhi-Cheng Li
- Jian-Yuan Meng
- Zhi-Yin Liang
- Liang Ma
- Ming-Song Wu
- Jia-Yong Su
- Ya-Qun Yu
- Jin-Min Wang
- On behalf of the RESOLVE-Lung investigators
- Guang-Cai Zheng
- Lin-Hong Xie
- Chuang Qin
- Yi-He Yan
- Teng-Xian Zhou
- Ning Peng
- Bang-De Xiang
- Zhen Liu
- Yi ZHANG
Institutions
- Guangxi Medical University (CN)
- Hengshui University (CN)
- Guilin Medical University (CN)
- Beihai People's Hospital (CN)
- Liuzhou Maternal and Child Health Hospital (CN)
- Liuzhou General Hospital (CN)
- Beibu Gulf University (CN)
- The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine (CN)
- Qingzhou City People's Hospital (CN)
- Wuzhou University (CN)
- Guigang City People's Hospital (CN)
- The People's Hospital of Guangxi Zhuang Autonomous Region (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
- Affiliated Hospital of Youjiang Medical University for Nationalities (CN)
- The Second Nanning People's Hospital (CN)
- Fourth Affiliated Hospital of Guangxi Medical University (CN)
- Baise University (CN)
- Affiliated Hospital of Guilin Medical College (CN)
- First People's Hospital of Nanning (CN)
- Hezhou University (CN)
- Wuzhou Red Cross Hospital (CN)
- Yulin University (CN)
Publication Details
- Journal
- Communications Medicine
- Published
- 2026-03-12
- DOI
- https://doi.org/10.1038/s43856-025-01303-w
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Guangxi Medical University
- Guangxi Key Research and Development Program